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ABSTRACT
Background and objectives: HIV among people
who inject drugs (PWID) is a major public health
concern in Eastern and Central Europe and Central
Asia. HIV transmission in this group is growing and
over 27 000 HIV cases were diagnosed among PWID
in 2010 alone. The objective of this systematic review
was to examine risk factors associated with HIV
prevalence among PWID in Central and Eastern Europe
and Central Asia and to describe the response to HIV
in this population and the policy environments in
which they live.
Design: A systematic review of peer-reviewed and
grey literature addressing HIV prevalence and risk
factors for HIV prevalence among PWID and a
synthesis of key resources describing the response to
HIV in this population. We used a comprehensive
search strategy across multiple electronic
databases to collect original research papers
addressing HIV prevalence and risk factors among
PWID since 2005. We summarised the extent of
key harm reduction interventions, and using a
simple index of ‘enabling’ environment described
the policy environments in which they are
implemented.
Studies reviewed: Of the 5644 research papers
identified from electronic databases and 40 documents
collected from our grey literature search, 70
documents provided unique estimates of HIV and 14
provided multivariate risk factors for HIV among PWID.
Results: HIV prevalence varies widely, with
generally low or medium (<5%) prevalence in Central
Europe and high (>10%) prevalence in Eastern
Europe. We found evidence for a number of structural
factors associated with HIV including gender, socio-
economic position and contact with law enforcement
agencies.
Conclusions: The HIV epidemic among PWID in the
region is varied, with the greatest burden generally in
Eastern Europe. Data suggest that the current response
to HIV among PWID is insufficient, and hindered by
multiple environmental barriers including restricted
access to services and unsupportive policy or social
environments.
INTRODUCTION
The HIV epidemics of Europe are diverse
but in all European countries HIV dispropor-
tionally affects populations that are socially
marginalised and people whose behaviour is
ARTICLE SUMMARY
Article focus
▪ A systematic review to identify and synthesise
prevalence estimates and risk factors for HIV
among people who inject drugs (PWID) in Central
and Eastern Europe and Central Asia.
▪ A summary of key data to describe the response
to HIV among PWID in Central and Eastern
Europe and Central Asia, including a brief char-
acterisation of the policy environments.
Key messages
▪ The review highlights that the HIV epidemic among
PWID in the region varies from country to country,
with Eastern European countries generally the
worst affected. Prevalence is extremely high
among PWID in many countries with some studies
suggesting more than one in two PWID are
infected with the virus in parts of Estonia, Russia
and Ukraine.
▪ Despite few studies explicitly examining environ-
mental factors, our review found that gender,
socio-economic position and contact with law
enforcement agencies to be associated with HIV
prevalence. The complex interplay between the
environment and individual behaviour of PWID is
not fully understood and further emphasis on
understanding the social epidemiology of HIV in
this group is needed.
▪ An integrated package of needle exchange pro-
grammes, opiate substitution therapy and anti-
retroviral therapy is core to an effective response to
HIV in this group. The coverage of such interven-
tions in the region varies from low to non-existent
and must be improved. Further resources coupled
with improvement in the policy environments are
key to reducing HIV transmission in this group.
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socially stigmatised or illegal. The epidemics in Eastern
Europe and Central Asia, which are predominantly asso-
ciated with injecting drug use, are among the fastest
growing in the world.1 Over two-thirds of all HIV diagno-
ses to date in Europe fall in Eastern Europe and Central
Asia, and over 70% of these emanate from Russia.2 3
Over 27 000, or over 30% of new cases of HIV were
attributed to injecting drug use in Central and Eastern
Europe and Central Asia in 2010.2 3 Almost all of these
(99·6%) were made in Eastern Europe and Central Asia.
Accounting for differences in absolute population size,
between 2006 and 2010, 89 new HIV diagnoses asso-
ciated with injecting drug use have been made on
average each year in the East per million people. This
contrasts with Central Europe where the rate is 100
times less at 0.8 per million.2
Because of low access to and uptake of HIV testing and
counselling—especially among the marginalised and stig-
matised populations most at risk of HIV infection and
transmission—not all HIV cases in Europe are diagnosed
and reported.4 Estimates suggest that reported cases
probably represent just over half of all people living with
HIV in Europe.4 It is estimated that just over 2.3 million
people were living with HIV in Europe in 2010, 840 000
in Western Europe and 1.5 million in Eastern Europe.4
There are an estimated 3.1 million people who inject
drugs (PWID) in Central and Eastern Europe and
Central Asia, of whom one million are estimated to be
HIV infected.5 In Russia alone, there are an estimated 1.8
million PWID, of whom around 700 000 are thought be
HIV infected.5 Estimates of the prevalence of HIV among
PWID in Central and Eastern Europe and Central Asia
vary widely, from zero in some Central European coun-
tries where injecting drug use is less widespread, to over
20% in some countries in Eastern Europe and Central
Asia, including Estonia, Moldova, Russia, and Ukraine.5 6
HIV and other blood-borne infections contribute sig-
niﬁcantly to the excess morbidity and mortality experi-
enced by PWID in Europe and elsewhere.7 8 HIV has
the potential to spread rapidly via the sharing of needles
and syringes between PWID as well as via unprotected
sex between PWID and their injecting and non-injecting
partners.
Social contexts of HIV epidemics
A growing body of work substantiates relationships
between health harms related to drug use and social-
material factors that shape vulnerability to HIV.9–16 The
heuristic of the HIV ‘risk environment’ envisages HIV risk
as the product of reciprocal relationships between micro-
level and macrolevel inﬂuences in the physical, social,
economic and policy environments which contextualise
individual and community actions in relation to risk.9–15
This interaction has been described as a reciprocal
process whereby individual actions are constrained as well
as enabled by their environments and in turn shape as
well as reproduce those contexts.17 Qualitative work
among PWID in Russia, for example, has illustrated how
reduced capacity for HIV risk reduction in the micro-
environment is shaped by street-level policing practices
which are in turn contextualised by broader structural
policies of criminalisation and cultural practices of mar-
ginalisation which taken together produce a collectively
internalised fear and sense of constrained agency among
PWID.17 18
Recent reviews have thus called for a shift towards social
epidemiological approaches.9–15 These investigate how
the distribution of HIV in populations is in part shaped
by ‘social factors’, that is, forces that extend beyond ‘prox-
imal’ individual-level factors and their biological media-
tors. This simultaneously demands a shift from binary
models of ‘cause and effect’ to ‘multilevel’ models, which
enable HIV risk to be understood as an effect of multiple
contributing factors, at once interacting together, includ-
ing potentially in ‘non-linear’ and ‘indirect’ ways.19
Delineating causal pathways to inform structural interven-
tions is thus a daunting yet critical challenge. Recent evi-
dence reviews suggest that currently the epidemiology of
HIV among PWID rarely explicitly embraces the study of
social determinants.20
The social and economic transitions transforming the
Central and Eastern European and Central Asian region
in the past 20 years have been abrupt, dramatic and long
lasting. In many countries of the region, economic uncer-
tainty has combined with weakening social capital, an
embryonic and fragile civil society, a poorly resourced
and overly vertically structured health system, and public
policies tackling drug use that have emphasised law
enforcement and security at the expense of public
health.16 21 Social and economic transformations follow-
ing the dramatic political change in Eastern European
and Central Asian countries have played a role in shaping
transitions in problematic substance use as well as vulner-
ability to HIV.21–26 The opening-up of international and
ARTICLE SUMMARY
Strengths and limitations of this study
▪ This review is the most comprehensive synthesis of HIV preva-
lence and risk factors among PWID in Central and Eastern
Europe and Central Asia to date and is complemented by a clear
synopsis of the state of the national policy environments and
responses to HIV for people who inject drugs.
▪ The quality of the review relies on quality of the original articles,
which are variable. The samples included are often selective as
many studies recruited participants from specialist services or via
drug user networks. Multivariate analyses are adjusted for a
variety of factors, rendering direct comparisons between
point-estimates difficult.
▪ The service coverage data are not measured in a standard
manner across the region, and is from different years. The quality
of data varies greatly by country, thus undermining the compari-
sons we can make about coverage.
▪ We use a crude index of ‘policy environment’ which is developed
from binary indicators that cannot account for important nuances
influencing intercountry and intracountry environments.
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trade borders, for instance, has facilitated population
mixing as well as the development of heroin trafﬁcking
routes from Afghanistan to the West, also linked to the
diffusion of heroin use.27 There was evidence of explosive
HIV outbreaks linked to injecting drug use in the former
Soviet region by the mid-1990s, especially in Russia,
Ukraine and Moldova.21
Enabling policy environments for HIV prevention
Recognising HIV epidemics as features of their social
and structural contexts emphasises the potentially
pivotal role of social and structural interventions in cre-
ating environments which are enabling, rather than con-
straining, of evidence-based HIV prevention.28–30 Key
dimensions of ‘enabling’ policy environments conducive
to effective HIV prevention for PWID include, but are
not restricted to: the meaningful engagement of key sta-
keholders (including PWID) in policy formation and
programming; a coordinated multisectoral national HIV
prevention strategy emphasising an evidence-based
public health and rights-oriented approach; the gener-
ation of research and surveillance on HIV epidemic
spread and response; and the development and scale-up
of a package of evidence-based interventions, including
the removal of structural obstacles limiting their imple-
mentation.31–33 This has led to calls to de-emphasise the
criminalisation of PWID by developing policies empha-
sising public health above law enforcement-dominated
approaches, and for the rapid scaling-up of harm reduc-
tion interventions including syringe exchange, opioid
substitution treatment (OST), and antiretroviral HIV
treatment (ART), as well as community action and social
support interventions.31 32 34–36
Review scope
We aim to systematically review epidemiological research
investigating the burden of HIV, and associated risk
factors, among PWID in Central and Eastern Europe and
Central Asia. We seek to identify the extent to which such
epidemiological research captures measures of the HIV
risk environment by delineating HIV risk factors identi-
ﬁed at the levels of the individual and environment. We
situate this epidemiological work by synthesising current
evidence reviews of the extent and availability of HIV pre-
vention targeting PWID in the region and by developing
a simple index of ‘enabling’ policy environment at the
country level.
METHODS
We reviewed data from the 30 Eastern and Central
European and Central Asian countries in WHO-deﬁned
Europe, including 15 from Eastern Europe and Central
Asia (Armenia, Azerbaijan, Belarus, Estonia, Georgia,
Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Republic of
Moldova, Russian Federation, Tajikistan, Turkmenistan,
Ukraine and Uzbekistan), ‘the East’ and 15 from Central
Europe (Albania, Bosnia and Herzegovina, Bulgaria,
Croatia, Cyprus, Czech Republic, Hungary, Macedonia
(FYR), Montenegro, Poland, Romania, Serbia, Slovakia,
Slovenia and Turkey), ‘the Centre’.
Search strategy and selection criteria
We systematically searched MEDLINE, EMBASE, Global
Health, Social Science Citation Index, Popline and
CINAHL for studies published from 2005 to 20 October
2011. To identify articles we combine four broad search
themes with the Boolean operator ‘AND’. The ﬁrst
theme, HIV, combined the Medical Subject Headings
(MESH) terms ‘HIV’ or ‘HIV infections’ with the free
word search for ‘HIV’, ‘human immunodeﬁciency virus’
with ‘OR’. The second theme, prevalence, incidence and
risk factors, included the MESH terms ‘prevalence’, ‘inci-
dence’, ‘risk’, ‘factor analysis’, ‘statistical’, ‘regression ana-
lysis’, ‘risk factors’, ‘risk-taking’ and ‘epidemiology’ with
the free words ‘prevalen*’, ‘incidence’, ‘risk*’, ‘correlat*’,
‘determinant*’, ‘vulnerab*’, ‘regression’, ‘risk’, ‘(enhan-
c*adj3) transmission’, ‘multivar*’, ‘(route*adj3 transmis-
sion)’, ‘ (factor*adj3 transmission)’, ‘social norm*’,
‘network’, ‘socio-demographic’, ‘socio-economic’, ‘life-
style’ and ‘epidemiol*’ with ‘OR’. The third theme, geo-
graphic coverage, included the names of the countries in
the region, as well as the free word terms ‘Europe*’ and
‘Central Asia*’ combined with ‘OR’. The fourth theme,
PWID, combined the MESH terms ‘substance abuse’,
‘intravenous’, ‘needle sharing’ and ‘heroin dependence’
with the free word terms ‘IDU*’, ‘inject*’, ‘intravenous’,
‘heroin’, ‘addict*’, ‘opiate*’, ‘narco*’, ‘psychotropic*’,
‘psychoactive*’, ‘drug depend#n*’, ‘(recreation*adj3
drug*)’, ‘harm reduction’, ‘syringe*’, ‘methadone’,
‘opioid*’, ‘syringe*’, ‘(needle*adj3 shar*)’, and ‘(illega-
l*adj3 drug*)’ combined with ‘OR’.
Additionally, we systematically searched websites of
research institutes, service providers, and donor organisa-
tions working with PWID across the region including
recent reports from countries reporting to the United
Nations General Assembly Special Session on HIV/AIDS
(UNGASS). We searched the website of the European
Monitoring Centre for Drugs and Drug Addition
(EMCDDA) for data and sources reported from member
and neighbouring countries. Conference abstracts from
the International Conference on the Reduction of Drug
Related Harm (2005–2011) and the International AIDS
Conference (2006, 2008 and 2010) were also searched.
Our review conformed to the PRISMA checklist for sys-
tematic reviews.37
Study selection and eligibility criteria
All abstracts were reviewed. Studies were excluded if they
were: (1) published before 2005; (2) fell outside the
deﬁned geographic region; (3) did not focus on HIV
among PWID; (4) did not sample PWID; or (5) did not
focus on bio-conﬁrmed HIV prevalence or incidence, or
injecting or sexual risk practices. Papers were also
excluded if they reported a sample size less than 50, had
unclear sampling methods or they contained no
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primary data, although the references were searched to
gather primary studies not identiﬁed by the search.
Papers not ﬁtting the inclusion criteria were set aside to
aid interpretation of the systematic review ﬁndings.
Figure 1 summarises the papers searched and retained
in the review. Following full-text review 100 peer-
reviewed and grey literature documents were identiﬁed
as meeting our criteria, of which 70 reported an inci-
dence or prevalence measure and 30 demographic or
risk factor data only. Of the 70 documents reporting
prevalence or incidence data, 14 included the results of
a multivariate analysis.
Two authors (EJ and LP) independently assessed the
quality of the studies reporting HIV prevalence esti-
mates using a scoring system that graded the papers
on: wide geographic coverage; most recent study;
population sampled; and recruitment setting. We allo-
cated up to three points each for most recent studies,
population sampled, country coverage and for the
range of settings sampled, and deducted one point for
drug treatment only samples due to the potential for
bias.38
Data extraction
The results of the multivariate studies meeting our inclu-
sion criteria were extracted as presented, regardless of
the strength of association. Comparable factors were
collected and examined using forest plots showing the
effect estimates and 95% CI. We classiﬁed the results of
the multivariate studies as ‘individual-level’ factors or
‘environmental-level’ factors based on the proximity
of the risk of the factor in terms of HIV transmission.
Individual-level risk characteristics or activities included
injecting and sexual risks, such as sharing needles or
unprotected sex, that shape an individual’s HIV risk
through direct biological mechanisms. Environmental-
level factors are those which have no direct biological
means of inﬂuencing HIV risk; however, their presence or
absence has been identiﬁed as an independent factor in
the risk faced by an individual, indicating their role in
shaping a ‘risk environment’.
Coverage of HIV prevention interventions
In addition to the systematic review, data summarising
the coverage of HIV prevention interventions was drawn
Figure 1 Flowchart of study selection.
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primarily from recently published reviews39 and previ-
ously published country-level data.40 These data are col-
lected from a variety of sources, including UNGASS,
WHO and systematic reviews of scientiﬁc literature,39 as
well as from routine national reports.40
Policy environment index
We generated a simple index of ‘enabling’ policy envir-
onment. Our interpretation of an enabling policy envir-
onment drew upon guidelines generated by WHO,41
UNAIDS,42 international non-government organisations
(NGOs)43 and peer-reviewed papers in this
ﬁeld.20 30 32 44 As outlined in box 1, the core items of
the index included indicators, at the country level, of:
coordinated national strategy to HIV prevention and
drug use (indicated by evidence of explicit inclusion of
‘harm reduction’ in national-level strategy, and monitor-
ing and evaluating HIV epidemics); meaningful engage-
ment of stakeholders in HIV prevention policy
formation and programming (indicated by evidence of a
national organisation of drug users); and evidence-based
HIV prevention intervention approaches (indicated by
presence of OST and NSP, presence of OST and NSP in
prison settings, and evidence of de-emphasising crimin-
alisation through the use of administrative penalties for
drug use possession for personal use).
Indicator data were obtained from a combination of
sources, including: global reports of harm reduction
policy and coverage;45 country proﬁles collated and
updated by the EMCDDA;46 our systematic review of
research studies (see above and ﬁgure 1); and the
International Network of People who Use Drugs (Albers
ER, personal communication with EJ, 2011). The index
was constructed by allocating equal weight to each of
the six items and aggregating a score for each country,
with higher scores indicating a more ‘enabling’ environ-
ment conducive to evidence-based public health
approaches.
RESULTS
HIV incidence
Only three papers reviewed reported HIV incidence
among PWID in this region. Two in Tallinn, Estonia,
reported an HIV incidence rate of 31/100 person-years
(PY) in 2004, decreasing to 9/100 PY in 2009 among
people injecting for less than 3 years.47 48 The other from
St. Petersburg, Russia, reported a rate of 4.5/100 PY.49
HIV prevalence
Estimates of HIV prevalence among PWID vary widely
throughout the region. A total of 79 sources reported
HIV prevalence estimates (some multiple), of which 67
reported unique HIV prevalence estimates among PWID
in the region; 44 from Eastern Europe and Central
Asia6 49–88 and 21 from Central Europe89–109 and two
that contained data from both regions.40 110
Multiple estimates exist for many countries (ﬁgure 2),
and where this was the case we applied the scoring
system described above (see Methods section) to select
Box 1 A simple index of enabling policy environment
Meaningful engagement of stakeholders
▸ The meaningful involvement of people who inject drugs (PWID)
in policies affecting their health and welfare and in related HIV
prevention programming is accepted as an important indicator
of ‘health policy’ formation.42 157 While assessing ‘meaningful
involvement’ is complex, we adopt a simple indicator: the pres-
ence of a national organisation of drug users.
Coordinated national strategy to HIV prevention and drug use
▸ Explicit and supportive reference to ‘harm reduction’ in national
policy documents can mark a commitment to evidence-based
interventions as part of HIV prevention responses targeting
PWID. International agencies advocate institutional and national-
level endorsement of harm reduction as a feature of national
strategy.33 158 We adopt evidence of explicit supportive reference
to harm reduction in national strategy as an indicator of enabling
policy environment.
▸ Monitoring and evaluating the state of the epidemic and
response are important elements of building evidence-based
responses.40 159 Targeted sero-prevalence and behavioural sur-
veillance is recommended in concentrated HIV epidemics.160
We adopt as an indicator of enabling policy evidence of at least
one HIV sero-prevalence and one behavioural study among
PWID since 2000.
Implementation of Public Health-oriented approaches to redu-
cing harm
▸ Drug control policies which seek to distinguish drug users
from drug traders and traffickers, and which de-emphasise the
criminalisation of drug users, can give priority to public
health-oriented approaches to reducing drug-related harm. We
adopt the application of administrative rather than criminal
penalties for drug use and possession of quantities for per-
sonal use as an indicator of an enabling policy environment.
▸ We adopt the legal availability of opioid substitution treatment
(OST) and needle and syringe distribution programmes (NSP)
in a country as an indicator of enabling policy environment.
These are core components of the recommended nine
combination HIV prevention interventions for PWID.33 Many
countries have adopted at least some recommended mea-
sures, but often the components missing are OST and NSPs.
The effectiveness of both in improving the health of PWID is
well established,32 154 161 especially for OST.162–168 OST also
facilitates access to and augments the effects of other inter-
ventions, such antiretroviral HIV treatment.32 151
▸ The availability of OST and NSPs in prison can show a country’s
willingness to address the needs of even the most marginalised
of its citizens, as well as demonstrating noteworthy scale of the
programmes. Because of existing laws concerning drug use and
possession, PWID in many countries account for disproportion-
ately high rates of incarceration.139 Prisons may act as a risk
environment for HIV transmission linked to drug injecting.
International guidelines169 recommend continuity of services
between prison and communities and some countries have
developed successful partnerships between penal systems and
HIV services, including in the European region.170
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the estimate that appeared to be most representative at
the country level. Using these estimates, we have cate-
gorised country HIV epidemics among PWID as: ‘low’
(up to 1%); ‘medium’ (2–5%); ‘high’ (5–20%); and
‘very high’ (greater than 20%).
No country in the East can be considered to have a
‘low level’ of HIV among PWID, and only Kazakhstan,
Georgia and Lithuania have ‘medium level’ epidemics,
according to the studies examined here. Of the remain-
ing 11 countries with data (no data exist for
Turkmenistan), three have prevalence estimates of over
20% (Moldova, Russia and Ukraine) and Estonia has a
prevalence of over 50%. In the Centre only Poland and
Bulgaria appear to have ‘high level’ epidemics and
neither of these exceed 10% prevalence. Several coun-
tries (Albania, Croatia, Cyprus, Hungary, Macedonia and
Slovenia) report 0% HIV prevalence among PWID.
However, there are less data from this region and sample
sizes are generally smaller so the estimates may be less
robust than those from the East.
Demographic profile
Generally, three times as many men as women inject
drugs, although male predominance reached as high as
95% in some studies from the Caucuses.50 54 55 62 64 85 111
The mean age of PWID participating in studies was
mid-20s, although many studies restrict recruitment to
PWID aged 18 or over. The proportion of PWID reporting
having regular income was generally low.
Pattern of injecting drug use
Heroin is the drug of choice among PWID in Europe,
although there are sub-regional differences. In
Moldova,112 Ukraine73 and Russia,52 the injection of
home-produced opioids such as ‘hanka’ or ‘shirka’
(a liquid poppy extract) is reported alongside heroin injec-
tion. In Estonia the use of the synthetic opiate, fentanyl
(‘China White’, ‘White Persian’ or ‘Afghan’), has become
common alongside amphetamine injection.71 113 In
Central Europe, heroin is reported as the main drug
injected, although studies also report between 30% and
51% injecting amphetamines as their main drug,100 114 115
and the Czech Republic reports the highest prevalence of
methamphetamine use in Europe.116–118 The frequency of
injection varies widely throughout the region.
Contact with criminal justice systems
The data reviewed from Eastern Europe and Central
Asia suggest that between half and three-quarters of
PWID have experienced arrest. A study among 600
PWID in Odessa, Ukraine found that police beatings
were common, with nearly 50% reporting at least one
such experience.20 119 Studies in other regions also
suggest relatively high rates of police arrest (42–76%
ever having been arrested).18 27 107 120 In Estonia and
Lithuania, an estimated 58–70% of PWID had been in
prison at least once.74 In Georgia and Russia, this ﬁgure
was between 6% and 37%,18 52 64 65 79 121 122 In Central
Europe, between 18% and 50% of respondents report
previously having been in prison.93 107
Individual-level risk factors for HIV
No studies examined risk factors linked to HIV in the
Centre, and so we summarise the ﬁndings of the multi-
variate HIV risk factor analyses from 14 papers identiﬁed
by our review in the East,49 51–53 57 65 72 73 88 113 121 123–125
although two65 72 present new analyses of data already
published in other papers also presented here.123 125
Table 1 summarises the key characteristics of the 14
papers as well as the factors explored in the multivariate
Figure 2 The range of HIV
prevalence estimates for
countries in the Central and
Eastern European region, along
with the estimate judged ‘best’
highlighted in green.
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Table 1 Summary of studies presenting multivariate analyses of risk factors for HIV among people who inject drugs (PWID) in Central and Eastern Europe and Central
Asia
Study (year) Location Sample Individual-level risk factors
Environmental-level
risk factors
Platt et al (2006)113 Estonia, Tallinn 350 PWID who injected in past 4 weeks
recruited by respondent-driven sampling
(RDS)
Primary injection of opioid or amphetamine in past
4 weeks*; Duration of injecting career;
Shared needle in past 4 weeks;
Shared equipment in past 4 weeks;
Injected with a used needle of a sex partner in past
4 weeks*;
Number of sexual partners in past year
Age;
Gender;
Main source of income
in past 4 weeks;
Ethnicity;
Ever registered in drug
treatment*;
Ever been in prison;
Ever attended needle
exchange
Abel-Ollo et al
(2009)71
Estonia, Tallinn
and Kohtla-Järve
450 PWID (350 from Tallinn and 100 from
Kohtla-Järve) who injected in past 4 weeks
recruited by RDS. For analysis the
participants were categorised as HIV-, HIV+
aware of their status and HIV+ unaware of
their status, according to self-reported status
at the time of testing
The data from Tallinn is also analysed above
Analysis of risk factors for HIV among participants
aware of their status (ref HIV participants):
Sharing used needles/syringes in past 4 weeks*;
Unprotected sex in past 4 weeks;
Sharing water*;
PWID as sex partner in past year*;
Sharing injection equipment with sexual partner in
past year*;
Having two or more sex partners in past year;
Unprotected intercourse in past year;
Ever sharing needles with HIV+ person*.
Analysis of risk factors for HIV among participants
unaware of their status (ref HIV- participants):
Sharing used needles/ syringes in past 4 weeks;
Unprotected sex in past 4 weeks;
Sharing water;
PWID as sex partner in past year;
Sharing injection equipment with sexual partner in
past year;
Having two or more sex partners in past year*;
Unprotected intercourse in past year*;
Ever sharing needles with HIV+ person.
Uusküla et al
(2010)88
Estonia, Tallinn 350 PWID, aged 18+, who injected in past
2 months recruited by RDS
Earlier age of initiation to injecting*;
Primary injection of opioid or amphetamine*;
Receptive sharing in past 6 months*
Ever attended syringe
exchange*;
Main source of income
other than work*;
Unemployment at
habitat level*;
Residential change at
habitat level*
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Table 1 Continued
Study (year) Location Sample Individual-level risk factors
Environmental-level
risk factors
Platt et al (2005)125 Russia, Togliatti 268 Male PWID who injected in past 4 weeks
recruited in 2001 by outreach workers
Duration of injection;
Injected with used paraphernalia in past 4 weeks*;
Injected with used needle in past 4 weeks;
Ever injected homemade drugs;
Injected with used needle from someone known to be
HIV+;
Injected with used needle from someone known to be
HCV+*;
Unprotected anal or vaginal sex with a regular partner
in past 4 weeks;
Unprotected anal or vaginal sex with a casual partner
in past 4 weeks*;
Ever had an STI
Ever been in prison;
Ever been in drug
treatment;
Ever been arrested
Russia, Togliatti 89 Female non-sex worker PWID who
injected in past 4 weeks recruited in 2001 by
outreach workers
Duration of injection;
Injected with used paraphernalia in past 4 weeks;
Injected with used needle in past 4 weeks*;
Ever injected homemade drugs;
Injected with used needle from someone known to be
HIV+;
Injected with used needle from someone known to be
HCV+;
Unprotected anal or vaginal sex with a regular partner
in past 4 weeks;
Ever had an STI
Ever been in prison;
Ever been in drug
treatment;
Ever been arrested
Russia, Togliatti 66 Female sex worker PWID who injected in
past 4 weeks recruited in 2001 by outreach
workers
Duration of injection;
Injected with used paraphernalia in past 4 weeks;
Injected with used needle in past 4 weeks;
Ever injected homemade drugs*;
Injected with used needle from someone known to be
HIV+;
Injected with used needle from someone known to be
hepatitis C virus+;
Unprotected anal or vaginal sex with a regular partner
in past 4 weeks;
Ever had an STI
Ever been in prison;
Ever been in drug
treatment;
Ever been arrested;
Platt et al, 200865 Russia, Togliatti 230 PWID (134 in 2001 from the study
above, and 96 from 2004) who reported
injecting for 3 years or less and injected in
past 4 weeks were recruited by outreach
workers in 2001 and through RDS in 2004
Duration of injecting career*;
Frequency of injection;
Ever injected homemade drugs;
Injected with used needles in past 4 weeks;
Used a previously used filter;
Frontloading in past 4 weeks*;
Year of study*;
Gender;
Age;
District of residence;
Education;
Main source of income
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Table 1 Continued
Study (year) Location Sample Individual-level risk factors
Environmental-level
risk factors
Injected with a prefilled syringe;
Frequency of reusing the same needle;
Ever exchanged sex for money, drugs or goods*;
History of STIs
in past 4 weeks;
History of prison;
Police arrest in past
year;
Ever in drug treatment*;
Main source of needles
in past 4 weeks;
Ever been tested for HIV
Kozlov et al
(2006)49
*outcome is HIV
incidence at
12 month follow up
to enrolment
Russia,
St. Petersburg
520 Sero-negative PWID enrolled in cohort
study who injected at least three times/week
in past month or reused another’s injecting
equipment at least three times in past
3 months
Frequency of injecting psychostimulants*;
Number of sex partners in past 6 months;
Selling sex for money or goods in past 6 months
Niccolai et al
(2010)121
Russia,
St. Petersburg
387 Ever injectors were enrolled through
RDS
Unsafe injection in past 30 days*;
Has STI*;
Unemployed*
Rhodes et al
(2006)52
Russia, Moscow 455 PWID who injected in past 4 weeks
recruited by outreach workers
Duration of injecting career;
Last day injected, number of times injected*;
Frequency of injection;
Main drug injected in past 4 weeks;
Injected with used needle in past 4 weeks;
Shared paraphernalia in past 4 weeks;
Ever injected with used needles*;
Number of sex partners in past year;
History of STI*
Gender;
Age;
Education;
Main source of income
in past 4 weeks;
Ever been in prison*;
Ever registered as a
drug user*
Russia, Volgograd 517 PWID who injected in past 4 weeks
recruited by outreach workers
Duration of injecting career;
Frequency of injection*;
Ever injected homemade drugs;
Injected with used needle in past 4 weeks;
Shared paraphernalia in past 3 weeks;
Ever injected with used needles;
Injected with needle previously used by sex partner in
past 12 months*;
Number of sex partners in past year;
History of STI
Gender;
Age;
Education;
Main source of income
in past 4 weeks*;
Ever registered as a
drug user
Russia, Barnaul 501 PWID who injected in past 4 weeks
recruited by outreach workers
Duration of injecting career;
Last day injected, number of times injected*;
Frequency of injection;
Main drug injected in past 4 weeks;
Ever injected homemade drugs;
Gender;
Age;
Education;
Main source of income
in past 4 weeks;
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Table 1 Continued
Study (year) Location Sample Individual-level risk factors
Environmental-level
risk factors
Injected with used needle in past 4 weeks;
Shared paraphernalia in past 4 weeks*;
Filled syringe from working syringe in past 4 weeks;
Ever injected with used needles;
Number of sex partners in past year;
History of STI
Ever been in prison;
Ever registered as a
drug user
Beyrer et al
(2009)72
Tajikistan,
Dushanbe
419 PWID who injected in past month aged
17 or over recruited through snowball
technique
Daily injection in past 6 months* Ethnicity*
Model adjusted for
gender
Stachowiak et al
(2006)123
Tajikistan,
Dushanbe
207 Ethnic Tajik PWID (subsample of above)
aged 17 or over recruited through snowball
technique
Injecting at least daily for past 6 months*;
Less than 3 years since initiation of injection;
Injects ‘alone’*;
Injected with used needle in past 6 months
Reports narcotics ‘very
easy’ to obtain*;
Ever experienced drug
treatment*
Booth et al (2006)51 Ukraine, Kiev,
Odessa,
Makeevka/
Donetsk
778 PWID aged 18+ who injected in past
30 days and were unaware of their HIV
status recruited through outreach workers
Injected sedative/ opiate mix in past 30 days*;
Daily injection in past 30 days*;
Sex in past 30 days*;
Sex with HIV+ or unknown status partner in past
30 days*
Age*;
Gender*;
City of origin*
Robbins et al
(2010)124
Ukraine, Odessa,
Kiev, Donetsk
313 Youth aged 15–24 who live part or full
time on the street and reported ever injecting
recruited by time–location sampling
Last sex unprotected*;
Ever diagnosed with STI*
Model adjusted for gender, age, education, work for
pay, orphan status, spending nights outside of
residence ≥2 nights/week for past few months/ no
place to live, city of residence
Dumchev et al
(2009)73
Ukraine, Vinnitsya 268 PWID aged 18+ who report at least
three injections in past 30 days and have
lived in Vinnitsya for past year, recruited
through snowball sampling
Shared needles with HIV+ person in past year*;
Inject opiates daily*
HIV knowledge score*
Taran et al (2011)57 Ukraine, 16 cities 3487 PWID aged 16+ who injected in past
30 days and were recruited through RDS
Type of drug injected in past month;
Duration of injecting career*;
Injecting frequency in past month;
Used alcohol with drugs in past month*;
Shared needle at last injection*;
Frequency of sharing paraphernalia in past month*;
Sexual contact in past year
Gender*;
Marital status;
Occupation*;
Education*
Sanchez et al
(2006)53
Uzbekistan,
Tashkent
701 Self-identified PWID aged 18+ available
for 2 weeks after enrolment by outreach
workers
Age at first drug use;
First illicit drug of use*;
Duration of injecting career;
Current heroin use;
Injecting frequency;
Age;
Gender;
Nationality;
Marital status;
Employment status*;
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analysis. The forest plots summarised in ﬁgures 3 and 4
synthesise the effects of particular individual and environ-
mental risk factors on HIV. Although studies measure
similar associations, it is important to note that each may
have carried out analyses in a unique manner, adjusting
for different confounding variables.
As shown by the individual risk factor estimates pre-
sented in ﬁgure 3, many studies investigated the link
between HIV and injecting with a used or shared needle.
Although the effect sizes tend towards increased HIV risk,
most results are inconclusive, ‘social-desirability’ bias pos-
sibly inﬂuencing self-reported responses. Injecting with
the used needle of a sex partner was found in
Volgograd52 and Tallinn113 to clearly increase an indivi-
dual’s odds of HIV. More deﬁnitively, injecting with a
needle previously used by someone known to have HIV
or hepatitis C is shown in most studies to be clearly posi-
tively correlated.72 125 Daily injecting is also found to be
positively associated. Many reviewed studies also associate
longer injecting careers with greater odds of having HIV.125
Although a Russian study found no difference in an indi-
vidual’s odds of HIV according to the primary drug they
inject,126 studies in Estonia found that primary injectors
of an opiate (fentanyl) had between three and four and
a half times greater odds of HIV than individuals who pri-
marily inject amphetamines.113 127
Regarding exploration of HIV and associated sexual risk
including sex work (SW), most multivariate analyses
explored the associations between exchanging sex for
drugs or money, the number of sexual partners, and
unprotected vaginal or anal sex, as risk factors. Although
several strong univariate associations were found, these
tended not to hold in the multivariate models (ﬁgure 3).
This could be because sample sizes were insufﬁcient or
because much sexual risk behaviour is determined by
other individual or environmental factors such as gender,
socio-economic status or injecting behaviour.
Environmental-level risk factors for HIV
Although most studies presented show adjusted ORs
(AOR) identifying female gender as a risk factor for HIV
(ﬁgure 4), the CIs generally straddle one and are
inconclusive.
Multiple studies link HIV to the socio-economic status of
PWID, though economic status is deﬁned through differ-
ent measures, including level of education, employment
(regular or not) and income (regular or not, legal or not;
ﬁgure 4). Of these measures, only an individual’s employ-
ment status showed a consistent association with HIV, with
unemployed individuals or those having a main source of
income that was not work, showing greater odds of HIV
than others.53 57 88 121 An Estonian multilevel study
included neighbourhood level data in its analyses and
found neighbourhood level effects of unemployment
(10% increment in unemployment AOR 5.95, 95% CI
2.47 to 14.31) and habitat change since 1989 (10% change
AOR 1.89, 95% CI 1.09 to 3.26) to be both associated with
HIV prevalence (results not presented).
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Several studies have examined contact with law enforce-
ment agencies as an environmental factor linked with the
odds of being HIV infected, although the results pro-
duced by the systematic review have large CIs and are
largely inconclusive.52 65 113 125 The review reveals that
contact between police and PWID in the region is highly
commonplace and no studies examined the frequency
or duration of contact.
In addition to the universally relevant factors high-
lighted above, some studies analysed the relationship
between HIV and determinants that are particular to
local context (results not shown). For example, a study
in Tajikistan found that respondents identifying as Tajik
(AOR 7.06, p<0.001) or other ethnicity (AOR 6.05,
p<0.001) as opposed to Russian were at higher risk of
testing positive for HIV.72 A study in Uzbekistan similarly
found respondents of Uzbek ethnicity to have higher
odds of HIV than their Russian counterparts (AOR 1.20,
95% CI 0.80 to 1.80).53 However, a study in Estonia
found that ethnic Estonians had a reduced odds of HIV
compared with those of Russian or other backgrounds
(AOR 0.63, 95% CI 0.28 to 1.25).113 In Moscow and
Tallinn ever having been registered as a PWID at drug
treatment was found to be associated with more than
double the odds of HIV (AOR 2.4, 95% CI 1.3 to 4.7;
AOR 2.4, 95% CI 1.5 to 3.8).52 113 Conversely, a study in
Togliatti in Russia conducted among 96 new (<3 years)
injectors found having been in drug treatment in the
past as negatively associated with risk of HIV (AOR 0.4,
95% CI 0.1 to 1.0).128
Figure 3 Adjusted effect estimates of individual level risk factors present in multivariate studies of PWID. *New people who
inject drugs (PWID) (≤3 years); **male PWID; †female (non- sex work (SW)) PWID; ‡female (SW) PWID.
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HIV prevention coverage
Coverage—the proportion of the population at risk
reached by an intervention, ideally with sufﬁcient inten-
sity to have probable impact—emerges as a critical deter-
minant of HIV prevention effectiveness.32 129–131 Our
review did not focus on collating primary data but sought
to synthesise coverage estimates relevant to the Central
and Eastern European and Central Asian region from key
recently published reviews regarding NSPs, OST and
ART.39 40 These data are contained in ﬁgure 5. They indi-
cate that NSPs were available in all countries of the
region, except for Turkey, though intervention coverage
varies widely. For instance, whereas 50% of PWID in
Hungary in 2007 had access to NSPs, with each receiving
around 135 clean needles a year (135 per PWID based on
country-level estimates of PWID), in Russia only 7% of
PWID had such access to NSPs, with each receiving 56
needles each a year (4 per PWID based on country-level
estimates of PWID). These estimates do not include
pharmacy-based provision, which is a primary source in
some countries in this region, including Russia.132
Figure 5 also shows that 4 of the 30 countries in this
region reporting evidence of injecting drug use did not
provide OST: Russia, Uzbekistan, Turkmenistan and
Turkey. Coverage of OST is generally low, with Slovenia
showing the greatest coverage.
Comparing the proportion of HIV cases caused by
injecting drug use with the corresponding proportion of
Figure 4 Adjusted effect estimates of environmental level risk factors present in multivariate studies of PWID. *New people who
inject drugs (PWID) (≤3 years); **male PWID; †female (non- sex work (SW)) PWID; ‡female (SW) PWID.
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people receiving antiretroviral therapy who inject drugs,
in 2002, 71% of the reported people living with HIV
acquired HIV infection through injecting drug use,
whereas only 20% of those receiving antiretroviral
therapy were people who injected drugs. In 2005 and
2006, among 21 and 23 countries with available data,
people who injected drugs represented 77% of reported
cases and 26% of antiretroviral therapy recipients, a pro-
portion that declined to 22% in 2010 among 19 report-
ing countries. Although no trends can be statistically
ascertained due to incomparable samples (notably
missing data from the Russian Federation in 2002 and
2010), these data suggest that most of the people who
acquire infection in reporting countries are people who
inject drugs and that, despite this, their treatment needs
remain considerably underserved.4
We found no data relating to the impact or coverage
of structural level interventions on HIV among PWID,
although recent legislative changes in Moldova and the
Czech Republic have de-emphasised the criminalisation
of small amounts of drugs possession.
Enabling policy environments
Figure 6 shows the results of the policy index developed
(see Methods section) to describe the distribution of
enabling policy environments throughout Central and
Eastern Europe and Central Asia. Darker shading repre-
sents seemingly more supportive policy environments
for HIV prevention and lighter shading seemingly less
supportive environments.
Of the 30 countries in the region, 25 explicitly and
supportively mentioned harm reduction in their
national strategies, and 27 have undertaken at least one
sero-prevalence and one behavioural study among PWID
in the last 10 years. In 26 countries, OST and NSP are
available generally, but available in prison in only three
countries. Five countries have national organisations of
drug users, and ﬁve countries use administrative rather
than criminal penalties for people found possessing
small quantities of drugs for personal use.
On the basis of the index, the countries with the most
supportive policy environments are Moldova and
Romania. The countries with the least supportive envir-
onments are Turkmenistan and Turkey. Turkmenistan
does not show any of the features of a supportive envir-
onment according to our index, although Turkey has
conducted at least one sero-prevalence and one behav-
ioural study among PWID in the last 10 years. In Russia,
where the majority share of HIV infections among
PWID in the region are located, the national strategy
refers to harm reduction as a threat to efforts to reduce
the demand for drugs, with NSPs and OST speciﬁcally
mentioned as problematic for federal level support.133
OST is unavailable in Russia, and NSPs are limited in
number, with none available to prisoners, and there is a
focus on criminal rather than administrative penalties
for drugs possession. However, there is some evidence of
drug user activism and organisation (Albers ER, per-
sonal communication with EJ, 2011).
Russia and Ukraine both feature among the countries
experiencing high HIV prevalence among PWID, and
Figure 5 Estimated numbers of syringes distributed per people who inject drugs (PWID) per year and estimated number of
opioid substitution treatment clients per 100 PWID in the latest year for which data is available.39 40
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like Russia, criminal punishment rather than administra-
tive sanctions for drug use and possession is the norm in
Ukraine. While Ukraine has a relatively high number of
NSPs alongside increasing availability of OST, it does not
provide harm reduction services in prisons. Moldova
and Estonia also feature among the high-HIV-prevalent
countries but both appear as to present relatively sup-
portive environments for PWID. However, to our knowl-
edge, neither has an active national drug user
organisation and neither NSP or OST in prison settings.
DISCUSSION
HIV epidemic contexts
All but one country (Turkmenistan) in Central and
Eastern Europe and Central Asia has generated survey-
based estimates of HIV prevalence among PWID. Our
review of these studies shows that HIV prevalence
among PWID is highest in the Eastern European coun-
tries of Estonia, Russia, Moldova and Ukraine (over 20%
in each), and lowest in the Central European countries
of Albania, Croatia, Cyprus, Hungary, Macedonia (FYR)
and Slovenia (0% in each). We identiﬁed only three
HIV incidence studies among PWID in the region,
showing an incidence of 9/100 PY in Estonia in 200948
and 4·5/100 PY in Russia.49 Accepting that country esti-
mates of HIV prevalence inevitably only reﬂect the char-
acteristics of the particular samples from which they are
drawn, these estimates taken together reiterate that the
burden of HIV linked to injecting drug use falls in the
East, and especially Russia, where over half of all HIV
cases among PWID in the region are located.
Multivariate analyses of HIV risk factors among PWID
underscore injecting with a used needle/syringe, fre-
quent injecting, and injecting opiates as opposed to
amphetamines as proximal factors associated with
increased risk of HIV. We acknowledge that the ﬁndings
of the multivariate studies we synthesise in the review
may not be directly comparable, as they have been
derived from studies using different regression
techniques and adjusting for different confounding
factors. While most of the epidemiological studies we
reviewed did not embrace, by design, the exploration of
environmental risk factors—as is the case with HIV epi-
demiological studies globally20—a number of important
factors in the HIV risk environment can be identiﬁed.
These included increased HIV risk among women, an
association we interpret to have indirect, rather than bio-
logical, causative roots through pathways involving mul-
tiple linked socio-economic differences related to
gender. Although most studies showed women at greater
risk of HIV than men, the CIs presented include the
null value, preventing us from drawing conclusions on
the effect of gender on HIV risk. The lack of conclusive
evidence could be due to the small number of women
often recruited in to research, as well as genuine vari-
ability in the consequences of female gender in different
settings. Qualitative data from Ukraine suggest that
female PWID are at increased risk of psychological, phys-
ical (including sexual) and economic violence from
their male partners, constraining capacity to negotiate
safer sex, safer injecting practices and access to helping
services, thus elevating their HIV risk.134
Additionally, socio-economic status—whether measured by
income or employment—emerged as important, although
only employment status appeared conclusively associated
with HIV risk. The direction and pathways income and
employment effects have on HIV risk may vary locally. The
ways in which HIV links to wealth and poverty is shaped by
social context, and in some settings injecting has diffused
among those whose economic status may be comparable
to the wider local population.52 135
Lastly, we note contact with criminal justice agencies,
including experience of incarceration, as an important
risk factor,52 65 113 125 although the studies systematically
reviewed here were inconclusive in this regard. Studies
evidencing the adverse effects of the legal environment
on HIV risk among PWID suggest a relationship
between street-based policing practices, including extra-
judicial ones such as police violence, and increased HIV
Figure 6 Map showing the supportiveness of the policy environments for HIV among people who inject drugs in Europe.
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vulnerability, including through reduced capacity for
risk avoidance as a consequence of safety short-cuts and
rushed injections borne out of a fear of detection or
arrest.18 27 119 136–138 While evidence internationally
links prison and a history of incarceration to elevated
odds of HIV among PWID,139 140 only three countries in
the region (Moldova, Romania and Kyrgyzstan) provide
harm reduction services to prisoners. An association
between HIV among PWID and being of a minority eth-
nicity that cannot otherwise be explained by needle
sharing has been noted elsewhere, and linked to mater-
ial as well as other social inequalities, including access to
support services.141 142 In parts of Eastern Europe and
Central Asia where PWID are often required to register
as such to obtain drug treatment or are forced to
through contact with police, this can lead to increased
social marginalisation as well as reducing their ability to
gain employment or even to drive a car.143
While the epidemiological studies we reviewed provide
some pointers to the role of HIV risk environments, they
are self-evidently limited in their capacity to capture
how HIV is an effect of social context. This highlights
the urgency to develop speciﬁcally tailored social epi-
demiological approaches, which build into their designs
from the outset measures of micro and macro risk
environment. It also highlights the importance of mixed-
methods approaches, especially those combining qualita-
tive with epidemiological data.144 For example, by linking
HIV epidemiology to data on shifting drug trafﬁcking
routes it has been possible to plot the macrophysical dis-
tribution of HIV.145 In the region of Central and Eastern
Europe and Central Asia, the potentially HIV risk pro-
ductive role of transit routes for heroin originating from
Afghanistan through Central Asian countries along the
‘Northern Route’ to Russia and beyond provides a similar
example. In 2009, UNODC estimated that 25% of all
Afghan heroin (95 metric tons) was transported along
this route, with the majority travelling through Tajikistan,
to Osh in Kyrgyzstan, and then on to Kazakhstan, before
arriving in Russia.146 The effects of this trafﬁcking route
appear to have HIV impacts with Kulyab, in Tajikistan, a
major hub for Afghan opiate trafﬁcking, reporting the
highest HIV prevalence among PWID in Tajikistan at
34.5% in 2009 compared with the national average of
17.3%.147 Jalal-Abad reported the highest HIV prevalence
among PWID in Kyrgyzstan at 14% in 2007148 compared
with a national average of 7·7%.83 In Kazakhstan, there is
substantial overlap between the sites with the largest
number of diagnosed HIV infections, largest number of
registered drug users and highest number of heroin
seizures.149
Future epidemiological studies of HIV among PWID
need to better systematically develop measures of HIV
risk environment and how these combine to increase or
reduce HIV risk.20 Because epidemiological studies of
PWID tend to focus on the proximal determinants of risk
behaviour and HIV transmission, there is a need to shift
towards capturing distal factors and how these interplay
to produce pathways of risk.19 20 28 150Principal among
these, according to our review, should be gender,
social-economic status, and the effects of criminalisation.
In addition to the limitations discussed above, the
study is subject to several potential biases including
missing key documents, especially those not published
in the English language. Individual studies may tend to
publish what are considered ‘interesting’ results, leading
to potential publication bias towards analyses reporting
signiﬁcant results. This can lead a systematic review such
as ours to overstate the effect of several factors. As some
elements of this review were undertaken by the same
authors, this may reduce protection against human
error and preservation of independence between the
stages of the review.
Towards enabling policy environments
It is well established that HIV prevention targeting PWID
requires a ‘combination intervention’ approach tailored to
local setting, including a balance of: needle and syringe
distribution programmes (NSPs); opioid substitution treat-
ment (OST); antiretroviral HIV treatment (ART); peer
education and outreach; HIV testing and counselling
services; and the promotion of public policies and other
structural changes conducive to public health
approaches.20 32 33 151–153 Evidence for the effectiveness of
these interventions is well established.32 151 154 155 The
extent of HIV prevention intervention coverage, however,
varies throughout the region, and is largely inad-
equate.39 40 Many of the countries with the lowest levels of
harm reduction service provision are also those with the
highest HIV prevalence and the largest per-capita number
of new diagnoses. The unavailability of OST in Russia in
particular means that the majority of PWID in the region
do not have access to an integral component of evidence-
based HIV prevention.
Structural interventions seek to remove environmental
barriers to HIV prevention while enabling environmen-
tal conditions which protect against vulnerability to HIV.
While the relationships between HIV-related policies
and their impacts upon micro-level HIV risk practices
are clearly not straight forward, the policy environment
is a clear object of structural intervention and change.
Our review identiﬁed no evidence speciﬁcally relating to
the impact or coverage of structural-level interventions
on HIV among PWID, although recent legislative
changes in Moldova and the Czech Republic have
de-emphasised the criminalisation of small amounts of
drug possession, and evidence elsewhere in Europe links
such initiatives with reduced HIV risk and increased
access to helping services.156
In the absence of social epidemiological data gener-
ated from systematic review, we developed a crude index
of ‘enabling policy environment’ based on indicators of:
national-level policy endorsing of harm reduction
approaches; research of HIV prevalence and risk behav-
iour among PWID; drug user community organisation;
availability of OST and NSPs; availability of OST and
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NSPs in prison settings; and application of administrative
rather than criminal penalties for drug use and posses-
sion (see box 1). Such an index seeks to include quanti-
ﬁable indicators of the practical application of ‘healthy
policy’, at least as far as such data is comparatively avail-
able. We acknowledge the limits of this exercise, but
argue for the need for future epidemiological research
to better monitor indicators of enabling and risk envir-
onment alongside proximal risk factors for HIV, espe-
cially those pertaining to community involvement and
partnership in policy formation, availability of HIV pre-
vention in criminal justice settings, and shifts towards
de-emphasising the criminalisation of drug use through
providing treatment or care as an alternative to arrest or
imprisonment.
Applying our index of enabling policy environment
highlighted large discrepancies throughout the region.
Of the countries with a seemingly unsupportive environ-
ment for HIV prevention among PWID, Turkmenistan
may present a particular concern, for it is located
between countries of high HIV prevalence, situated on a
heroin trafﬁcking route and appears to lack a baseline
of epidemiological evidence. Other countries—includ-
ing Russia, Uzbekistan and Azerbaijan—appear to
present weak policy environments for HIV prevention,
compounding potential risk linked to low-level HIV pre-
vention coverage. The lack of systematic monitoring of
policy environment indicators in the region, and the
neglected attention paid to monitoring the effect of
structural-level factors on microrisk relationships in epi-
demiological research, hampers an understanding of
how European HIV epidemic contexts may differ mark-
edly regarding HIV prevention need and potential. The
development of structural HIV prevention interventions
as part of a combination intervention approach clearly
requires evidence of how environmental-level factors
impact upon HIV risk.
The importance of reducing vulnerability to HIV/
AIDS, by understanding and removing structural bar-
riers, is increasingly recognised in European HIV policy,
for example as one of the four strategic directions of the
European Action Plan for HIV/AIDS 2012–2015, which
proposes actions to: address laws and regulations that
present obstacles to effective HIV prevention, treatment
care and support; strengthen the enforcement of pro-
tective laws and regulations; strengthen civil society
involvement in the HIV response and ensure gender
and age equity in access to HIV and related health
services.
Author affiliations
1Centre for Research on Drugs and Health Behaviour, London School of
Hygiene and Tropical Medicine, London, UK
2Centre for Infections, Health Protection Agency, London, UK
3Eurasian Harm Reduction Network, Vilnius, Lithuania
4Global Health Research Center of Central Asia, Columbia University,
New York, New York, USA
5Division of Communicable Diseases, Health Security and Environment, World
Health Organization Regional Office for Europe, Copenhagen, Denmark
6Global HIV/AIDS Programme, World Bank, Washington DC, USA
Contributors TR, LP and VH developed the methodology for the systematic
review. TR, LP, VH, AL and EJ reviewed the collected literature. EJ and VH
extracted the data. EJ conducted the data analysis. TR and EJ interpreted the
data and drafted the manuscript. All authors reviewed the manuscript and
commented on the data and interpretation. All authors gave approval for the
manuscript to be submitted.
Funding This review was undertaken as part of a larger project funded by the
World Bank to review HIV in vulnerable populations in Europe, grant number
7153690.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
REFERENCES
1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global
report: UNAIDS report on the global AIDS epidemic 2010, 2010.
2. European Centre for Disease Prevention and Control/WHO
Regional Office for Europe. HIV/AIDS surveillance in Europe 2010.
Stockholm: European Centre for Disease Prevention and Control,
2011.
3. Department of Health and Social Development of Russian
Federation, Federal Service for supervision of Consumer Protection
and Human Welfare, Federal Government Central Science
Research Agency Institute of Epidemiology, Federal Research and
Methodological Center for Prevention and Control of AIDS. HIV
INFECTION Newsletter№ 35. Moscow, 2011.
4. UNAIDS. Global HIV/AIDS response: epidemic update and health
sector progress towards Universal Access. Progress Report 2011.
5. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of
injecting drug use and HIV among people who inject drugs: a
systematic review. Lancet 2008;372:1733–45.
6. UNGASS. ed. UNGASS Country Progress Report: Republic of
Moldova. Chisinau, Moldova, 2010.
7. Bargagli AM, Hickman M, Davoli M, et al. Drug-related mortality
and its impact on adult mortality in eight European countries. Eur J
Pub Health 2006;16:198–202.
8. Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to
estimate mortality among injecting drug users that is not attributable
to AIDS. Sex Transm Infect 2006;82(suppl 3):iii56–63.
9. Cusick L. Widening the harm reduction agenda: from drug use to
sex work. Int J Drug Policy 2006;17:3–11.
10. Poundstone KE, Strathdee S, Celentano DD. The social
epidemiology of human immunodeficiency virus/acquired
immunodeficiency syndrome. Epidemiol Rev 2004;26:25–35.
11. Rhodes T. The ‘risk environment’: a framework for understanding
and reducing drug-related harm. Int J Drug Policy 2002;13:85–94.
12. Rhodes T, Singer M, Bourgois P, et al. The social structural
production of HIV risk among injecting drug users. Soc Sci Med
2005;61:1026–44.
13. Sumartojo E. Structural factors in HIV prevention: concepts,
examples, and implications for research. Aids 2000;14(suppl 1):
S3–10.
14. Latkin CA, Hua W, Forman VL. The relationship between social
network characteristics and exchanging sex for drugs or money
among drug users in Baltimore, MD, USA. Int J STD AIDS
2003;14:770–75.
15. Latkin C, Mandell W, Vlahov D, et al. Personal network
characteristics as antecedents to needle-sharing and shooting
gallery attendance. Social Netw 1995;17:219–28.
16. Donoghoe MC, Lazarus JV, Matic S. HIV/AIDS in the transitional
countries of eastern Europe and central Asia. Clin Med J R College
Physicians 2005;5:487–90.
17. Rhodes T, Wagner K, Strathdee SA, et al. Structural violence and
structural vulnerability within the risk environment: theoretical and
methodological perspectives for a social epidemiology of HIV risk
among injection drug users and sex workers. In: O’Campo P,
Dunn JR, eds. Rethinking social epidemiology: towards a science
of change. Springer: London, 2011.
18. Sarang A, Rhodes T, Sheon N, et al. Policing drug users in Russia:
risk, fear, and structural violence. Subst Use Misuse
2010;45:813–64.
19. Galea S, Hall C, Kaplan GA. Social epidemiology and complex
system dynamic modelling as applied to health behaviour and drug
use research. Int J Drug Policy 2009;20:209–16.
Jolley E, Rhodes T, Platt L, et al. BMJ Open 2012;2:e001465. doi:10.1136/bmjopen-2012-001465 17
HIV and people who inject drugs in Central and Eastern Europe and Central Asia
20. Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk
environment for injecting drug users: the past, present, and future.
Lancet 2010;376:268–84.
21. Rhodes T, Ball A, Stimson GV, et al. HIV infection associated with
drug injecting in the Newly Independent States, eastern Europe:
the social and economic context of epidemics. Addiction
1999;94:1323–36.
22. Bjerregaard P. Rapid socio-cultural change and health in the Arctic.
Int J Circumpolar Health 2001;60:102–11.
23. Durkheim E. Suicide. London: Routledge, 2002.
24. McKee M, Leon DA. Social transition and substance abuse
Addiction 2005;100:1205–9.
25. Leon DA, Chenet L, Shkolnikov VM, et al. Huge variation in
Russian mortality rates 1984–94: artefact, alcohol, or what? Lancet
1997;350:383–8.
26. Barnett T, Whiteside A, Khodakevich L, et al. The HIV/AIDS
epidemic in Ukraine: its potential social and economic impact. Soc
Sci Med 2000;51:1387–403.
27. Rhodes T, Mikhailova L, Sarang A, et al. Situational factors
influencing drug injecting, risk reduction and syringe exchange in
Togliatti City, Russian Federation: a qualitative study of micro risk
environment. Soc Sci Med 2003;57:39–54.
28. Gupta GR, Parkhurst JO, Ogden JA, et al. Structural approaches to
HIV prevention. Lancet 2008;372:764–75.
29. Blankenship K, Friedman S, Dworkin S, et al. Structural
interventions: concepts, challenges and opportunities for research.
J Urban Health 2006;83:59–72.
30. Rhodes T, Simic M. Transition and the HIV risk environment. BMJ
2005;331:220–3.
31. World Health Organisation (WHO). Policy and Programming Guide for
HIV/ Aids Prevention and Care among Injecting Drug Users, 2005.
32. Degenhardt LMB, Vickerman P, Rhodes T, et al. Prevention of HIV
infection for people who inject drugs: why individual, structural, and
combination approaches are needed. Lancet 2010;376:285–301.
33. World Health Organisation (WHO). WHO, UNODC, UNAIDS
Technical Guide for countries to set targets for universal access to
HIV prevention, treatment and care for injecting drug users, 2009.
34. Beyrer C, Malinowska-Sempruch K, Kamarulzaman A, et al. Time
to act: a call for comprehensive responses to HIV in people who
use drugs. Lancet 2010;376:551–63.
35. Wood E, Werb D, Marshall BD, et al. The war on drugs: a
devastating public-policy disaster. Lancet 2009;373:989–90.
36. Joint United Nations Program on AIDS (UNAIDS). International
Guidelines on HIV/AIDS and Human Rights: 2006 Consolidated
Version, 2006.
37. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for
reporting systematic reviews and meta-analyses of studies that
evaluate health care interventions: explanation and elaboration. J
Clin Epidemiol 2009;62:e1–34.
38. Watters JK, Biernacki P. Targeted sampling: options for the study
of hidden populations. Soc Problems 1989;46:416–30.
39. Mathers BMDL, Ali H, Wiessing L, et al. HIV prevention, treatment,
and care services for people who inject drugs: a systematic review
of global, regional, and national coverage. Lancet
2010;375:1014–28.
40. European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA). Statistical bulletin 2011. Secondary Statistical bulletin
2011 2011. http://www.emcdda.europa.eu/stats11 (accessed 18
Jan 2012).
41. World Health Organisation (WHO). Adelaide recommendations on
healthy public policy. Geneva: World Health Organization, 1988.
42. Reference Group to the United Nations on HIV and Injecting Drug
Use. Consensus Statement of the Reference Group to the United
Nations on HIV and Injecting Drug Use 2010.
43. International HIV/AIDS Alliance (Secretariat). Enabling Legal
Environments for Effective HIV Responses, 2010.
44. Tawil O, Verster A, O’Reilly KR. Enabling approaches for HIV/AIDS
prevention: can we modify the environment and minimize the risk?
AIDS 1995;9:1299–306.
45. International Harm Reduction Association. The Global State of
Harm Reduction 2010: key issues for broadening the response. In:
Cook C., 2010.
46. European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA). Country Overviews. Secondary Country Overviews
2011. http://www.emcdda.europa.eu/publications/country-overviews
(accessed 18 Jan 2012).
47. Uuskula A, Kals M, Rajaleid K, et al. High-prevalence and
high-estimated incidence of HIV infection among new injecting
drug users in Estonia: need for large scale prevention programs.
J Public Health 2008;30:119–25.
48. Uuskula A, Jarlais DCD, Kals M, et al. Expanded syringe exchange
programs and reduced HIV infection among new injection drug
users in Tallinn, Estonia. Bmc Public Health 2011;11.
49. Kozlov AP, Shaboltas AV, Toussova OV, et al. HIV incidence and
factors associated with HIV acquisition among injection drug users
in St Petersburg, Russia. AIDS 2006;20:901–6.
50. Smolskaya TT, Yakovleva AA, Kasumov VK, et al. HIV Sentinel
Surveillance in High-Risk Groups in Azerbaijan, Republic of
Moldova and in the Russian Federation. Europe: World Health
Organisation (WHO), 2004.
51. Booth REKC, Brewster JT, Sinitsyna L, et al. Predictors of HIV
sero-status among drug injectors at three Ukraine sites. AIDS
2006;20:2217–23.
52. Rhodes T, Platt L, Maximova S, et al. Prevalence of HIV, hepatitis
C and syphilis among injecting drug users in Russia: a multi-city
study. Addiction 2006;101:252–66.
53. Sanchez JLTC, Bautista CT, Botros BA, et al. High HIV prevalence
and risk factors among injection drug users in Tashkent,
Uzbekistan, 2003–2004. Drug Alcohol Depend 2006;82:S15–22.
54. Shapatava ENK, Tsertsvadze T, del Rio C. Risk behaviors and
HIV, hepatitis B, and hepatitis C seroprevalence among injection
drug users in Georgia. Drug Alcohol Depend 2006;82:S35–8.
55. Stvilia K, Tsertsvadze T, Sharvadze L, et al. Prevalence of hepatitis
C, HIV, and risk behaviors for blood-borne infections: a
population-based survey of the adult population of T’bilisi, Republic
of Georgia. J Urban Health 2006;83:289–98.
56. Gyarmathy VA, Li N, Tobin KE, et al. Unprotected sex in
heterosexual partnerships of injecting drug users in St. Petersburg,
Russia. AIDS Behav 2011;15:58–64.
57. Taran YS, Johnston LG, Pohorila NB, et al. Correlates of HIV Risk
among injecting drug users in sixteen Ukrainian cities. AIDS Behav
2011;15:65–74.
58. Dershem L, Tabatadze M, Tsereteli N, et al. Characteristics,
high-risk behaviors and knowledge of STI/HIV/AIDS, and STI/HIV
prevalence of facility-based female sex workers in Batumi, Georgia:
2004–2006. Report on two behavioral surveillance surveys with a
biomarker component for the SHIP Project. (Tbilisi), Georgia: Save
the Children, September, 2007.
59. Uuskula A, McNutt LA, Dehovitz J, et al. High prevalence of
blood-borne virus infections and high-risk behaviour among
injecting drug users in Tallinn, Estonia. Int J STD AIDS
2007;18:41–6.
60. Wilson TESA, Zilmer K, Kalikova N, et al. The HIV prevention
needs of injection drug users in Estonia. Int J STD AIDS
2007;18:389–91.
61. Abdala N, Krasnoselskikh TV, Durante AJ, et al. Sexually
transmitted infections, sexual risk behaviors and the risk of
heterosexual spread of HIV among and beyond IDUs in
St. Petersburg, Russia. Eur Addict Res 2008;14:19–25.
62. Gambashidze N, Sikharulidze Z, Piralishvili G, et al. Evaluation of
pilot methadone maintenance therapy in Georgia (Caucuses).
Georgian Med News 2008;7–8:160–1.
63. Inogamov ZI. State of the HIV epidemic in the Republic of
Uzbekistan Results of the SS in 2007: the results of sentinel
surveillance of HIV infection among injecting drug users in 14
sentinel sites of the Republic of Uzbekistan, 2007. Tashkent,
Uzbekistan, 2008.
64. Kuniholm MH, Aladashvili M, Rio CD, et al. Not all injection drug
users are created equal: heterogeneity of HIV, hepatitis C virus,
and hepatitis B virus infection in Georgia. Subst Use Misuse
2008;43:1424–37.
65. Platt L, Rhodes T, Hickman M, et al. Changes in HIV prevalence
and risk among new injecting drug users in a Russian city of high
HIV prevalence. J Acquir Immune Defic Syndr2008;47:623–31.
66. Raj A, Cheng DM, Krupitsky EM, et al. Correlates of any condom
use among Russian narcology patients reporting recent
unprotected sex. AIDS Behav 2008;13:310–17.
67. SOCIS-CSPS IIHAAiU. Monitoring the behaviour of injecting drug
users. Kyiv, Ukraine, 2008.
68. Todadze KLG. Implementation of drug substitution therapy in
Georgia. Cent Eur J Public Health 2008;16:121–3.
69. UNGASS. ed. Country progress report: Republic of Armenia. 2008.
70. UNGASS. ed. Republic of Belarus: National Report on the
Implementation of the Declaration of Committment on HIV/AIDS.
Minsk, Belarus, 2008.
71. Abel-Ollo K, Rahu M, Rajaleid K, et al. Knowledge of HIV
serostatus and risk behaviour among injecting drug users in
Estonia. AIDS Care 2009;21:851–7.
72. Beyrer C, Patel Z, Stachowiak JA, et al. Characterization of the
emerging HIV type 1 and HCV epidemics among injecting drug
18 Jolley E, Rhodes T, Platt L, et al. BMJ Open 2012;2:e001465. doi:10.1136/bmjopen-2012-001465
HIV and people who inject drugs in Central and Eastern Europe and Central Asia
users in Dushanbe, Tajikistan. AIDS Res Hum Retroviruses
2009;25:853–60.
73. Dumchev KV, Soldyshev R, Qian H-Z, et al. HIV and hepatitis C
virus infections among Hanka injection drug users in central
Ukraine: a cross-sectional survey. Harm Reduct J 2009;6:23.
74. Expanding Network for Comprehensive and Coordinated Action on
HIV/AIDS prevention among IDUs and Bridging Population
(ENCAP). Prevalence of HIV and other infections and risk
behaviour among Injecting Drug Users in Latvia, Lithuania and
Estonia in 2007, 2009.
75. Gyarmathy VA, Li N, Tobin KE, et al. Correlates of unsafe
equipment sharing among injecting drug users in St. Petersburg,
Russia. Eur Addict Res 2009;15:163–70.
76. Kryukova V. Overview of epidemiological situation & national
response to HIV-infection epidemic in Central Asian countries. 4th
Central Asian HIV Partnership Forum, 2009.
77. Niccolai LM, Shcherbakova IS, Toussova OV, et al. The potential
for bridging of HIV transmission in the Russian Federation: sex risk
behaviors and HIV prevalence among drug users (DUs) and their
non-DU sex partners. J Urban Health 2009;86(suppl 1):131–43.
78. UNGASS, ed. UNGASS Country Progress Report: Latvia. 2010.
79. Abdala NWE, Toussova OV, Krasnoselskikh TV, et al. Comparing
sexual risks and patterns of alcohol and drug use between injection
drug users (IDUs) and non-IDUs who report sexual partnerships
with IDUs in St. Petersburg, Russia. BMC Public Health
2010;10:676.
80. Federal Service for Surveillance of Consumer Rights Protection
and Human Well-Being Ministry of Health and Social Development
of the Russian Federation. Country Progress Report of the Russian
Federation on the Implementation of the Declaration of
Commitment on HIV/AIDS. Moscow, 2010.
81. Kechin EA. Studies conducted within the National System for
monitoring and evaluation of HIV/AIDS in the Republic of Belarus
in 2009: a collection of articles. In: Kechin EA. Minsk: State
Republican Center of Hygiene, Epidemiology and Public Health,
2010.
82. Pohorila N, Taran Y, Kolodiy I, et al. Behavior monitoring and
HIV-infection prevalence among injection drug users. Kyiv: ICF
‘International HIV/AIDS Alliance in Ukraine’, 2010.
83. Soliev A. Analysis on epidemiological situation and responses
based on second generation sentinel surveillance system among
injecting drug users, Tajikistan, Kazakhstan, Kyrgyzstan, 2006–
2009, 2010.
84. UNGASS, ed. UNGASS Country Progress Report: Republic of
Armenia. 2010.
85. UNGASS. UNGASS Country Progress Report: Georgia, 2010.
86. UNGASS, ed. UNGASS Country Progress Report: Estonia. 2010.
87. UNGASS. UNGASS Country Progress Report: Azerbaijan. 2010.
88. Uuskula A, McMahon JM, Raag M, et al. Emergent properties of
HIV risk among injection drug users in Tallinn, Estonia: synthesis of
individual and neighbourhood-level factors. (Special Issue:
Epidemiology and prevention of STDs: the role of emergent
properties and structural patterns.). Sex Transm Infect 2010;86
(suppl 3):iii79–84.
89. Family Health International (FHI). Albania—Behavioral and
Biological Surveillance Study Report, 2006.
90. UNGASS, ed. National AIDS Program: UNGASS Country Progress
Report: Albania. 2010.
91. UNICEF. Biological and behavioural survey among injection drug
users. Bosnia and Herzegovina: UNICEF Bosnia and Herzegovina,
2007.
92. Bacak V, Midžic D, Puhalo A, et al. Report on behavioral and
biological surveillance among injection drug users in Bosnia and
Herzegovina, 2009: a respondent driven sampling survey, 2009.
93. Vassilev ZP, Hagan H, Lyubenova A, et al. Needle exchange use,
sexual risk behaviour, and the prevalence of HIV, hepatitis B virus,
and hepatitis C virus infections among Bulgarian injection drug
users. Int J STD AIDS 2006;17:621–6.
94. UNGASS, ed. Country Progress Report on Monitoring the
Declaration of Committment on HIV/AIDS: Republic of Bulgaria.
2010.
95. Gjenero-Margan I, Kolari B. Epidemiology of HIV infection and
AIDS in Croatia—an overview. Coll Antropol 2006:11–16.
96. Begovac J, Zekan S, Skoko-Poljak D, et al. Twenty years of human
immunodeficiency virus infection in Croatia—an epidemic that is
still in an early stage. Antropol 2006;30:17–23.
97. UNGASS, ed. UNGASS Country Progress Report: Republic of
Croatia. 2010.
98. Bruckova MBC, Graham RR, Maly M, et al. Short report: HIV
infection among commercial sex workers and injecting drug users
in the Czech Republic. Am J Trop Med Hyg 2006;75:1017–20.
99. Gyarmathy AV, Neaigus A, Ujhelyi E. Vulnerability to drug-related
infections and co-infections among injecting drug users in
Budapest, Hungary. Eur J Public Health 2009;19:260–5.
100. Rácz J, Gyarmathy VA, Neaigus A, et al. Injecting equipment
sharing and perception of HIV and hepatitis risk among injecting
drug users in Budapest. AIDS Care Psychol Socio-Med Aspects
AIDS/HIV 2007;19:59–66.
101. UNGASS, ed. UNGASS Country Progress Report: Hungary. 2010.
102. Family Health International (FHI) I. Behavioural and Biological
Survey Kosovo 2006, 2006.
103. UNGASS, ed. UNGASS Country Progress Report: Republic of
Macedonia. 2010.
104. UNGASS, ed. UNGASS Country Progress Report: Montenegro.
2010.
105. United Nations Office on Drugs and Crime (UNODC). HIV, HBV
and HCV Behavioral Surveillance Survey among Injecting Drug
Users in Bucharest, Romania. Bucharest, 2010.
106. UNGASS, ed. UNGASS Country Progress Report: Republic of
Serbia. 2010.
107. Judd A, Rhodes T, Johnston LG, et al. Improving survey methods
in sero-epidemiological studies of injecting drug users: a case
example of two cross sectional surveys in Serbia and Montenegro.
BMC Infect Dis 2009;9:14.
108. UNGASS, ed. UNGASS Country Progress Report: Slovenia.
Turkey, 2010.
109. ICON Institute for Public Health. Operational Research on key STIs
and HIV in Turkey. Ankara, Turkey, 2007.
110. Gyarmathy VA, Neaigus A, Li N, et al. Liquid drugs and high dead
space syringes may keep HIV and HCV prevalence high—a
comparison of Hungary and Lithuania. Eur Addict Res
2010;16:220–28.
111. Chikovani I, Bozicevic I, Goguadze K, et al. Unsafe injection and
sexual risk behavior among injecting drug users in Georgia. J
Urban Health-Bulletin NY Acad Med 2011;88:736–48.
112. Scutelniciuc O, Ilinschi E. Assessment of Risk of HIV infection
among Most at Risk Adolescents. Chisinau: Ministry of Health of
the Republic of Moldova, National Center of Health Management
Monitoring and Evaluation of National Health Programmes,
National Drug Observatory, 2009.
113. Platt L, Bobrova N, Rhodes T, et al. High HIV prevalence among
injecting drug users in Estonia: implications for understanding the
risk environment. AIDS 2006;20:2120–3.
114. Gyarmathy V, Neaigus A. Marginalized and socially integrated
groups of IDUs in Hungary: potential bridges of HIV infection.
J Urban Health 2005;82:iv101–12.
115. Márványkövi F, Melles K, Rácz J. Sex and drugs: the correlations
of injecting drug users’ risk perception and behavioral patterns.
Subst Use Misuse 2009;44:569–77.
116. Colfax G, Santos G-M, Chu P, et al. Amphetamine-group
substances and HIV. Lancet 2010;376:458–74.
117. Griffiths P, Mravcik V, Lopez D, et al. Quite a lot of smoke but very
limited fire—the use of methamphetamine in Europe. Drug Alcohol
Rev 2008;27:236–42.
118. Grund J-P, Zabransky T, Irvin K, et al. Stimulant use in central and
eastern Europe: how recent social history shaped current drug
consumption patterns. In: Pates R, Riley D, eds. Interventions for
amphetamine misuse. Oxford: Wiley Blackwell, 2009.
119. Booth R, Dvoryak S, Anderson C, et al. Police brutality is
independently associated with sharing injection equipment among
injection drug users in Odessa, Ukraine. XVIII International AIDS
Conference; Vienna, Austria, 2010.
120. Cooper H, Moore L, Gruskin S, et al. The impact of a police drug
crackdown on drug injectors’ ability to practice harm reduction:
A qualitative study. Soc Sci Med 2005;61:673–84.
121. Niccolai LM, Toussova OV, Verevochkin SV, et al. High HIV
prevalence, suboptimal HIV testing, and low knowledge of
HIV-positive serostatus among injection drug users in
St. Petersburg, Russia. AIDS Behav 2010;14:932–41.
122. Des Jarlais DC, Grund J-P, Zadoretzky C, et al. HIV risk behaviour
among participants of syringe exchange programmes in
central/eastern Europe and Russia. Int J Drug Policy
2002;13:165–74.
123. Stachowiak JATF, Strathdee SA, Stibich MA, et al. Marked ethnic
differences in HIV prevalence and risk behaviors among injection
drug users in Dushanbe, Tajikistan, 2004. Drug Alcohol Depend
2006;82:S7–14.
124. Robbins CL, Zapata L, Kissin DM, et al. Multicity HIV
seroprevalence in street youth, Ukraine. Int J STD AIDS
2010;21:489–96.
125. Platt L, Rhodes T, Lowndes CM, et al. Impact of gender and sex
work on sexual and injecting risk behaviors and their association
Jolley E, Rhodes T, Platt L, et al. BMJ Open 2012;2:e001465. doi:10.1136/bmjopen-2012-001465 19
HIV and people who inject drugs in Central and Eastern Europe and Central Asia
with HIV positivity among injecting drug users in an HIV epidemic in
Togliatti City, Russian Federation. Sex Trans Dis 2005;32:605–12.
126. Platt L, Rhodes T, Judd A, et al. Effects of sex work on the
prevalence of syphilis among injection drug users in 3 Russian
cities. Am J Public Health 2007;97:478–85.
127. Uusküla A, Des Jarlais D, Kals M, et al. Outcomes of large-scale
syringe exchange in Tallinn, Estonia. XVIII International AIDS
Conference. Vienna, Austria, 2010.
128. Platt L, Rhodes T, Hickman M, et al. Changes in HIV prevalence
and risk among new injecting drug users in a Russian City of high
HIV prevalence. J Acquir Immune Defic Syndr 2008;47:623–31.
129. Wiessing L, Likatavicius G, Klempova D, et al. Associations
between availability and coverage of HIV-prevention measures and
subsequent incidence of diagnosed HIV infection among injection
drug users. Am J Public Health 2009;99:1049–52.
130. Vickerman P, Hickman M, Rhodes T, et al. Model projections on
the required coverage of syringe distribution to prevent HIV
epidemics among injecting drug users. J Acquir Immune Defic
Syndr 2006;42:355–61.
131. Heimer R. Community coverage and HIV prevention: assessing
metrics for estimating HIV incidence through syringe exchange. Int
J Drug Policy 2008;19(suppl 1):65–73.
132. Sarang A, Rhodes T, Platt L. Access to syringes in three Russian
cities: implications for syringe distribution and coverage. Int J Drug
Policy 2008;19(suppl 1):25–36.
133. Presidential Decree. State Anti-Drug Policy Strategy of the Russian
Federation in the Period until 2020, 2010.
134. Varban M, Dovbakh A, Maksymenko K. Violence of sexual partner
as a vulnerability factor of female IDU to HIV infection. XVIII
International AIDS Conference; Vienna, Austria, 2010.
135. Wall M, Schmidt E, Sarang A, et al. Sex, drugs and economic
behaviour in Russia: a study of socio-economic characteristics of
high risk populations. Int J Drug Policy 2011;22:133–9.
136. Rhodes T, Sarang A, Simic M. Police violence and ‘fear-based
policy’ as barriers to HIV prevention: qualitative case studies in
Russia and Serbia. XVIII International AIDS Conference; Vienna,
Austria, 2010.
137. Rhodes T, Prodanovic A, Zikic B, et al. Trust, disruption and
responsibility in accounts of injecting equipment sharing and
hepatitis C risk. Health Risk Soc 2008;10:221–40.
138. Burris S, Blankenship KM, Donoghoe M, et al. Addressing the ‘risk
environment’ for injection drug users: the mysterious case of the
missing cop. Milbank Q 2004;82:125–56.
139. Dolan K, Kite B, Black E, et al. HIV in prison in low-income and
middle-income countries. Lancet Infect Dis 2007;7:32–41.
140. Jürgens R, Ball A, Verster A. Interventions to reduce HIV
transmission related to injecting drug use in prison. Lancet Infect
Dis 2009;9:57–66.
141. Des Jarlais DC, Bramson H, Wong C, et al. Meta-analysis of the
international literature on racial/ethnic disparities in HIV infection
among IDUs: first results. XVIII International AIDS Conference;
Vienna, Austria, 2010.
142. Ursan M, Bocai A, Iliuta C, et al. Harm reduction initiative for roma
injecting drug users. International Harm Reduction Conference;
Bangkok, 2009.
143. Bobrova N, Rhodes T, Power R, et al. Barriers to accessing drug
treatment in Russia: a qualitative study among injecting drug users
in two cities. Drug Alcohol Depend 2006;82:S57–63.
144. Wagner KD, Davidson PJ, Pollini RA, et al. Reconciling
incongruous qualitative and quantitative findings in mixed methods
research: exemplars from research with drug using populations. Int
J Drug Policy 2012;23:54–61.
145. Beyrer C, Razak MH, Lisam K, et al. Overland heroin trafficking
routes and HIV-1 spread in south and south-east Asia. AIDS
2000;14:75–83.
146. United Nations Office on Drugs and Crime (UNODC). World Drug
Report 2010. Sales No. E.10.XI.13 ed: United Nations Publication,
2010.
147. Tumanov T, Asadulovev K, Chariev N. Analysis of epidemiological
situation and response measures based on the data from second
generation system sentinel surveillance among injecting drug users
in the Republic of Tajikistan in 2009. Dushanbe, 2010.
148. Ismailova A. Epidemiological surveillance of HIV infection in Kyrgyz
Republic. 2009.
149. United Nations Office on Drugs and Crime (UNODC) Regional
Office for Central Asia. Illicit Drug Trends in Central Asia, 2008.
150. Rhodes T. Risk environments and drug harms: a social science for
harm reduction approach. Int J Drug Policy 2009;20:193–201.
151. Van Den Berg C, Smit C, Van Brussel G, et al. Full participation in
harm reduction programmes is associated with decreased risk for
human immunodeficiency virus and hepatitis C virus: evidence
from the Amsterdam Cohort Studies among drug users. Addiction
2007;102:1454–62.
152. Grund J-P, Coffin P, Jauffret-Roustide M, et al. The fast and furious
—cocaine, amphetamines and harm reduction. In: Rhodes T,
Hedrich D, eds. Harm reduction: evidence, impacts and
challenges. Luxembourg: Publications Office of the European
Union, 2010:191–232.
153. Rhodes T, Hedrich D. Harm reduction and the mainstream. In:
Rhodes T, Hedrich D, eds. Harm reduction: evidence, impacts and
challenges. Luxembourg: Publications Office of the European
Union, 2010:462.
154. Kimber J, Palmateer N, Hutchinson S, et al. Harm reduction among
injecting drug users—evidence of effectiveness. In: Rhodes T,
Hedrich D, eds. Harm reduction: evidence, impacts and
challenges. Luxembourg: Publications Office of the European
Union, 2010:462.
155. Palmateer N, Kimber J, Hickman M, et al. Evidence for the
effectiveness of sterile injecting equipment provision in preventing
hepatitis C and human immunodeficiency virus transmission
among injecting drug users: a review of reviews. Addiction
2010;105:844–59.
156. Greenwald G. Drug Decriminalization in Portugal: Lessons for
Creating Fair and Successful Drug Policies: The Cato Institute, 2009.
157. Jürgens R. ‘Nothing about us without us’ — Greater, meaningful
involvement of people who use illegal drugs: A public health,
ethical, and human rights imperative, International edition. Toronto:
Canadian HIV/AIDS Legal Network, International HIV/AIDS
Alliance, Open Society Institute, 2008.
158. European Union (EU). EU Drugs Strategy (2005–2012). In:
Secretariat G. 2004.
159. UNAIDS. Practical guidelines for intensifying HIV prevention:
towards universal access. Geneva: UNAIDS, 2007.
160. UNAIDS/WHO. Guidelines for Second Generation HIV
Surveillance: The Next Decade. Geneva, Switzerland, 2000:48.
161. Tilson H, Aramrattana A, Bozzette S. Preventing HIV infection
among injecting drug users in high-risk countries: an assessment
of the evidence. Washington, DC: Institute of Medicine, 2007.
162. Williams AB, McNelly EA, Williams AE, et al. Methadone
maintenance treatment and HIV type 1 seroconversion among
injecting drug users. AIDS Care Psychol Socio-Med Aspects AIDS/
HIV 1992;4:35–41.
163. Metzger DS. Human immunodeficiency virus seroconversion
among intravenous drug users in- and out-of-treatment : an
18-month prospective follow-up. J Acquir Immune Defic Syndr
1993;6:1049–56.
164. Moss AR, Vranizan K, Gorter R, et al. HIV seroconversion in
intravenous drug users in San Francisco, 1985–1990. AIDS
1994;8:223–32.
165. Hartel DM, Schoenbaum EE. Methadone treatment protects
against HIV infection: two decades of experience in the Bronx,
New York City. Public Health Reports (Washington, DC: 1974)
1998;113(suppl 1):107–15.
166. Serpelloni G, Carrieri MP, Rezza G, et al. Methadone treatment as
a determinant of HIV risk reduction among injecting drug users: a
nested case-control study. AIDS Care: Psychol Socio-Med Aspects
AIDS/HIV 1994;6:215–20.
167. Novick DM, Joseph H, Scott Croxson T, et al. Absence of antibody
to human immunodeficiency virus in long-term, socially
rehabilitated methadone maintenance patients. Chicago, IL:
American Medical Association, 1990.
168. Rhoades HM, Creson D, Elk R, et al. Retention, HIV risk, and illicit
drug use during treatment: methadone dose and visit frequency.
Am J Public Health 1998;88:34–9.
169. World Health Organisation (WHO) UNOoDaCU, Joint United
Nations Programme on HIV/AIDS (UNAIDS). Interventions to
Address HIV in Prisons: HIV Care, Treatment and support.
Evidence for Action Technical Papers, 2007.
170. Larisa P. Drug Users, HIV-positive Prisoners. Examples of
adequate influence over changes in national policy on harm
reduction programs in Moldovan prisons. XVIII International AIDS
Conference; Vienna, Austria, 2010.
20 Jolley E, Rhodes T, Platt L, et al. BMJ Open 2012;2:e001465. doi:10.1136/bmjopen-2012-001465
HIV and people who inject drugs in Central and Eastern Europe and Central Asia
